Suzuki Takefumi, Uchida Hiroyuki, Takeuchi Hiroyoshi, Nomura Kensuke, Tanabe Akira, Watanabe Koichiro, Yagi Gohei, Kashima Haruo
Department of Neuropsychiatry, School of Medicine, Keio University, 35 Shinanomachi, Shinjuku, Tokyo, 160-8582, Japan.
Psychopharmacology (Berl). 2005 Sep;181(3):566-75. doi: 10.1007/s00213-005-0018-3. Epub 2005 Oct 12.
Taking psychotropic medications is frequently problematic from both consumers' and caregivers' perspective. Occasionally missed doses may lead to pervasive non-adherence with relapse a likely outcome.
To evaluate the simple medication regimen, all psychotropics were given at night for patients with chronic schizophrenia, who had been taking them at least twice a day for more than 12 weeks before the entry.
Switching of agents took place in two ways: converting only antipsychotic medications followed by other psychotropics, and changing all psychotropics simultaneously. Any psychotropics of little clinical significance were then cautiously minimized. Final evaluation was made 12 weeks after the competed dose consolidation. Patients finally rated their subjective impression on this intervention.
Twenty-five patients were recruited in each treatment arm (50 in total). After switching, 11 got better, 29 remained stable whereas seven got worse, according to the Global Improvement. Three were not assessable. Overall, there were no relevant changes in clinical ratings including adverse effects. However, the chlorpromazine equivalent dose of antipsychotics and the number of total psychotropics were significantly reduced from 957 to 722 mg/day (p<0.0001) and from 4.0 to 3.2 (p<0.0001), respectively. Dose deflation of psychotropics was feasible in 35 subjects (74.5%). Twenty-six (of 40 successful) patients indicated that they favored the night-time regimen mainly because it was less complicated. Sedation in the morning was identified as an important adverse event, which should be addressed by reducing the dose.
The procedure may be of value to counteract a recent trend of psychotropic polypharmacy in schizophrenia.
从消费者和护理人员的角度来看,服用精神药物常常存在问题。偶尔漏服可能导致普遍的不依从性,复发很可能是结果。
为评估简单的药物治疗方案,对慢性精神分裂症患者,在入组前至少12周每天服用精神药物至少两次,所有精神药物均在夜间服用。
药物转换通过两种方式进行:仅转换抗精神病药物,随后转换其他精神药物,以及同时更换所有精神药物。然后谨慎减少任何临床意义不大的精神药物。在完成剂量巩固12周后进行最终评估。患者最终对该干预措施给出主观评价。
每个治疗组招募了25名患者(共50名)。转换后,根据整体改善情况,11名患者病情好转,29名患者病情稳定,7名患者病情恶化。3名患者无法评估。总体而言,包括不良反应在内的临床评分没有相关变化。然而,抗精神病药物的氯丙嗪等效剂量和精神药物总数分别从957毫克/天显著降至722毫克/天(p<0.0001)和从4.0降至3.2(p<0.0001)。35名受试者(74.5%)实现了精神药物剂量缩减。40名成功患者中有26名表示他们更喜欢夜间治疗方案,主要是因为它不太复杂。早上的镇静被确定为一个重要的不良事件,应通过减少剂量来解决。
该程序可能有助于应对近期精神分裂症患者精神药物联合使用增多的趋势。